These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8392342)

  • 1. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.
    Solary E; Leteurtre F; Paull KD; Scudiero D; Hamel E; Pommier Y
    Biochem Pharmacol; 1993 Jun; 45(12):2449-56. PubMed ID: 8392342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines.
    Eymin B; Solary E; Chevillard S; Dubrez L; Goldwasser F; Duchamp O; Genne P; Leteurtre F; Pommier Y
    Int J Cancer; 1995 Oct; 63(2):268-75. PubMed ID: 7591216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azatoxin derivatives with potent and selective action on topoisomerase II.
    Leteurtre F; Sackett DL; Madalengoitia J; Kohlhagen G; MacDonald T; Hamel E; Paull KD; Pommier Y
    Biochem Pharmacol; 1995 May; 49(9):1283-90. PubMed ID: 7763310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.
    Leteurtre F; Madalengoitia J; Orr A; Guzi TJ; Lehnert E; Macdonald T; Pommier Y
    Cancer Res; 1992 Aug; 52(16):4478-83. PubMed ID: 1322792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
    Cline SD; Macdonald TL; Osheroff N
    Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.
    Chang JY; Han FS; Liu SY; Wang ZQ; Lee KH; Cheng YC
    Cancer Res; 1991 Apr; 51(7):1755-9. PubMed ID: 1848478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
    Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
    J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
    Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
    Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Biological Activity of Ferrocenyl and Ruthenocenyl Analogues of Etoposide: Discovery of a Novel Dual Inhibitor of Topoisomerase II Activity and Tubulin Polymerization.
    Chrabąszcz K; Błauż A; Gruchała M; Wachulec M; Rychlik B; Plażuk D
    Chemistry; 2021 Apr; 27(20):6254-6262. PubMed ID: 33465263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
    Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
    Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
    Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
    Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent.
    Chang JY; Hsieh HP; Pan WY; Liou JP; Bey SJ; Chen LT; Liu JF; Song JS
    Biochem Pharmacol; 2003 Jun; 65(12):2009-19. PubMed ID: 12787881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
    Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
    Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
    Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
    Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
    Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
    Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of DNA topoisomerase II by azaelliptitoxins functionalized in the variable substituent domain.
    Tepe JJ; Madalengoitia JS; Slunt KM; Werbovetz KW; Spoors PG; Macdonald TL
    J Med Chem; 1996 May; 39(11):2188-96. PubMed ID: 8667362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
    La Regina G; Bai R; Coluccia A; Naccarato V; Famiglini V; Nalli M; Masci D; Verrico A; Rovella P; Mazzoccoli C; Da Pozzo E; Cavallini C; Martini C; Vultaggio S; Dondio G; Varasi M; Mercurio C; Hamel E; Lavia P; Silvestri R
    Eur J Med Chem; 2018 May; 152():283-297. PubMed ID: 29730191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.